Animal Drug Compounding Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Animal Type, By Route of Administration, By Region & Competition, 2021-2031F

Description

The Global Animal Drug Compounding Market is projected to expand from USD 1.77 Billion in 2025 to USD 2.86 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.33%. This specialized sector involves licensed professionals manipulating pharmaceutical ingredients to produce customized medications for animals when approved commercial drugs are unavailable or inappropriate. The market's upward trajectory is primarily sustained by the growing medicalization of companion animals and the clinical requirement for dosage forms and flavorings tailored to specific species to guarantee treatment compliance. Rather than representing fleeting market shifts, these factors signify a lasting advancement in the veterinary care standards demanded by livestock producers and pet owners alike.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.77 Billion
Market Size 2031	USD 2.86 Billion
CAGR 2026-2031	8.33%
Fastest Growing Segment	Companion Animal
Largest Market	North America

One significant obstacle hindering market progression is the heightened regulatory oversight concerning bulk drug substances, which places heavy compliance responsibilities on compounding pharmacies and restricts access to specific preparations. Despite these regulatory difficulties, the industry's economic base remains strong, supported by persistent consumer spending on animal health. Data from the American Pet Products Association indicates that expenditures on veterinary care and product sales in the United States reached $39.8 billion in 2024. This significant financial dedication highlights the market's durability and the ongoing need for personalized veterinary pharmacotherapy.

Market Driver

The discontinuation and shortage of commercial veterinary drugs act as primary catalysts for the Global Animal Drug Compounding Market by generating urgent therapeutic gaps that only customized medications can bridge. As pharmaceutical companies cease production of older, less profitable drugs or face significant supply chain obstacles, veterinarians increasingly depend on compounding pharmacies to ensure continuity of care for essential treatments. This dependency is growing as the disparity between clinical necessities and commercial availability widens. According to the Canadian Veterinary Medical Association in November 2025, veterinarians in Canada have effectively lost access to 40% of the medications formerly used for patient care, transforming the compounding sector from an auxiliary service into a vital infrastructure that prevents manufacturing instability from compromising animal health.

Concurrently, the increasing rates of pet adoption and the humanization of companion animals are fundamentally changing the scale and intricacy of pharmaceutical requirements. Owners who regard their pets as essential family members are seeking sophisticated medical treatments and species-specific formulations, such as transdermal gels or flavored liquids, to enhance adherence and quality of life. This cultural evolution is reflected in significant ownership growth, with Animal Medicines Australia reporting in September 2025 that pet ownership has risen to include 73% of households nationally. This demographic trend underpins a robust economic landscape for animal health, further demonstrated by Zoetis Inc., which reported third-quarter revenue of $2.4 billion in November 2025 due to enduring demand for companion animal therapies.

Market Challenge

The central hurdle obstructing the Global Animal Drug Compounding Market's development is the escalating regulatory scrutiny surrounding the utilization of bulk drug substances. Authorities are rigorously implementing guidelines that restrict pharmacists from compounding medications using bulk active ingredients, mandating a preference for FDA-approved commercial products even if those options are not the ideal fit for a specific animal's condition. This regulatory stance creates a significant impediment to market growth, as compounding pharmacies are forced to absorb higher operational expenses and administrative tasks to demonstrate compliance. Consequently, numerous facilities are compelled to limit their product ranges or withdraw from the animal health sector entirely, thereby diminishing the overall accessibility of customized veterinary medications.

This constrained environment significantly hampers the market's capacity to react to supply chain deficiencies. For example, the Alliance for Pharmacy Compounding reported in 2024 that 28% of surveyed compounding pharmacies prepared amoxicillin suspension explicitly to alleviate commercial shortages. When regulations restrict the use of bulk substances, they reduce the flexibility needed to manage such critical shortfalls. By enforcing these strict boundaries, the industry encounters a bottleneck where the provision of tailored medications cannot sufficiently expand to satisfy the changing requirements of veterinarians and livestock producers, ultimately stagnating the market's broader expansion.

Market Trends

The growth of 503B outsourcing facilities dedicated to office-use stock is profoundly transforming the supply chain, as veterinarians search for compliant methods to sustain inventory amidst stricter regulations on traditional compounding. In contrast to 503A pharmacies, which are limited to patient-specific prescriptions, 503B facilities function under federal Good Manufacturing Practices (cGMP), enabling the production of bulk preparations with longer shelf lives that clinics can legally stock for immediate use. This structural evolution is prompting capital investment into facility improvements to satisfy the rising demand for standardized, compliant veterinary drugs. As reported by JobsOhio in September 2024, Wedgewood Connect Ohio declared a capital investment of $5.5 million to enlarge its FDA-registered 503B outsourcing facility, thereby enhancing its capacity to manufacture and supply these essential bulk formulations.

At the same time, market consolidation driven by strategic mergers and acquisitions is gaining momentum as leading competitors absorb specialized capabilities and extend their geographic reach. Dominant firms are purchasing regional pharmacies and technology platforms to secure a greater portion of the fragmented compounding market and optimize operations across both veterinary and human sectors. This aggregation enables companies to exploit economies of scale while broadening their portfolios to encompass hazardous, sterile, and non-sterile compounding services within a single entity. This trend is illustrated by recent significant transactions; for example, DVM360 reported in December 2024 that Grey Wolf Animal Health Corp acquired the Compounding Pharmacy of Manitoba for $22.5 million to strengthen its pharmacy division and widen its service capabilities in the Canadian market.

Key Market Players

Wedgewood Village Pharmacy, LLC
Vimian Group AB
Pharmaca Health Intelligence Ltd
Akina Animal Health
Triangle Compounding Pharmacy
Davis Islands Pharmacy & Compounding Lab
Custom Med Compounding Pharmacy
Central Compounding Center South
Wellness Compounding Pharmacy of Cary
Millers Pharmacy

Report Scope

In this report, the Global Animal Drug Compounding Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Drug Compounding Market, By Product

Anti-infective Agents
Anti-inflammatory Agents
Hormones & Substitutes
CNS Agents
Others

Animal Drug Compounding Market, By Animal Type

Companion Animal
Livestock Animal

Animal Drug Compounding Market, By Route of Administration

Oral
Injectable
Topical
Others

Animal Drug Compounding Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Drug Compounding Market.

Available Customizations:

Global Animal Drug Compounding Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Drug Compounding Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, Others)
- 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
- 5.2.3. By Route of Administration (Oral, Injectable, Topical, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Animal Drug Compounding Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Animal Type
- 6.2.3. By Route of Administration
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Animal Drug Compounding Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Animal Type
    - 6.3.1.2.3. By Route of Administration
- 6.3.2. Canada Animal Drug Compounding Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Animal Type
    - 6.3.2.2.3. By Route of Administration
- 6.3.3. Mexico Animal Drug Compounding Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Animal Type
    - 6.3.3.2.3. By Route of Administration

7. Europe Animal Drug Compounding Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Animal Type
- 7.2.3. By Route of Administration
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Animal Drug Compounding Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Animal Type
    - 7.3.1.2.3. By Route of Administration
- 7.3.2. France Animal Drug Compounding Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Animal Type
    - 7.3.2.2.3. By Route of Administration
- 7.3.3. United Kingdom Animal Drug Compounding Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Animal Type
    - 7.3.3.2.3. By Route of Administration
- 7.3.4. Italy Animal Drug Compounding Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Animal Type
    - 7.3.4.2.3. By Route of Administration
- 7.3.5. Spain Animal Drug Compounding Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Animal Type
    - 7.3.5.2.3. By Route of Administration

8. Asia Pacific Animal Drug Compounding Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Animal Type
- 8.2.3. By Route of Administration
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Animal Drug Compounding Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Animal Type
    - 8.3.1.2.3. By Route of Administration
- 8.3.2. India Animal Drug Compounding Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Animal Type
    - 8.3.2.2.3. By Route of Administration
- 8.3.3. Japan Animal Drug Compounding Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Animal Type
    - 8.3.3.2.3. By Route of Administration
- 8.3.4. South Korea Animal Drug Compounding Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Animal Type
    - 8.3.4.2.3. By Route of Administration
- 8.3.5. Australia Animal Drug Compounding Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Animal Type
    - 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Animal Drug Compounding Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Animal Type
- 9.2.3. By Route of Administration
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Animal Drug Compounding Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Animal Type
    - 9.3.1.2.3. By Route of Administration
- 9.3.2. UAE Animal Drug Compounding Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Animal Type
    - 9.3.2.2.3. By Route of Administration
- 9.3.3. South Africa Animal Drug Compounding Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Animal Type
    - 9.3.3.2.3. By Route of Administration

10. South America Animal Drug Compounding Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Animal Type
- 10.2.3. By Route of Administration
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Animal Drug Compounding Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Animal Type
    - 10.3.1.2.3. By Route of Administration
- 10.3.2. Colombia Animal Drug Compounding Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Animal Type
    - 10.3.2.2.3. By Route of Administration
- 10.3.3. Argentina Animal Drug Compounding Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Animal Type
    - 10.3.3.2.3. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Animal Drug Compounding Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Wedgewood Village Pharmacy, LLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Vimian Group AB
15.3. Pharmaca Health Intelligence Ltd
15.4. Akina Animal Health
15.5. Triangle Compounding Pharmacy
15.6. Davis Islands Pharmacy & Compounding Lab
15.7. Custom Med Compounding Pharmacy
15.8. Central Compounding Center South
15.9. Wellness Compounding Pharmacy of Cary
15.10. Millers Pharmacy